About Us

A lead-optimization stage biopharma­ceutical company

We are working on a first-in-class series of anti-cancer molecules that reactivate a key tumor suppressor, protein phosphatase 2A (PP2A). Rappta's proprietary tools and understanding of the target allow us to therapeutically reactivate PP2A, a critical enzyme regulating protein de-phosphorylation and tumor growth.

Protein Phosphatase 2A

PP2A’s structure, function, and roles in disease

Reversible phosphorylation is a fundamental mechanism to control all cell signaling and communication and this process is regulated through the opposing actions of phosphatases and kinases. Altered cellular signaling as a result of protein hyperphosphorylation, results in sustained proliferative signaling, and is a hallmark of human cancer development.

Protein Phosphatase 2A (PP2A) is a serine/threonine phosphatase that functions as a tumor suppressor by negatively regulating multiple oncogenic signaling pathways responsible for driving cancer progression. PP2A is made up of three subunits, that form a complete and active enzyme when bound together. The active enzyme is comprised of a scaffolding subunit (A), serving as the structural platform for the assembly of the catalytic (C) subunit and one substrate directing regulatory (B) subunit. In cancer, the tumor suppressive activity of PP2A is often disrupted as a result of the inability of the three subunits to bind together correctly, rendering the PP2A enzyme inactive. This inactivation of PP2A, leads to increased oncogenic signaling, driving cancer progression and growth. Therefore, the reactivation of PP2A affords a unique therapeutic strategy to restore PP2A activity and cellular homeostasis, that can potentially be used for the treatment of cancer and a broad range of other diseases.

Our approach

Our proprietary approach to activate PP2A

Rappta’s scientific team includes pre-eminent PP2A scientists who have published extensively on PP2A chemistry and biology. Based on our deep understanding of PP2A biology and proprietary tools we have developed compounds that reactivate PP2A and launched a program to develop these compounds into a new class of anti-cancer drugs.

Our small molecule compounds act as a glue to allow for the three subunits of PP2A to bind together driving PP2A complex reformation to target a wide array of oncogenic substrates. By solving a high-resolution structure of PP2A-Drug complex, we have been able to develop an entire new series of compounds to interlock the PP2A subunits and specifically reactivate its tumor suppressive function.